The antisense method is a technique used to manipulate gene expression by interfering with the RNA molecules that carry genetic information.
In the context of splicing-associated diseases, this method can be used to create animal models that mimic the disease phenotype by altering the splicing of specific genes.
Splicing is the process by which segments of RNA are removed and the remaining:
segments are joined together to animal tsunami strain create a mature mRNA molecule that can be translated into protein. Mutations in genes that affect splicing can lead to diseases such as spinal muscular atrophy and cystic fibrosis.
The antisense method involves designing and synthesizing short RNA molecules called:
antisense oligonucleotides (ASOs) that are complementary to specific sequences in the pre-mRNA molecule. When these ASOs bind to the pre-mRNA,
they can alter the splicing of the gene, resulting in the production of an aberrant mRNA molecule and ultimately a dysfunctional protein.
By using ASOs to manipulate splicing in animal models:
researchers can create phenocopies of splicing-associated diseases and study the molecular and physiological effects of the disease.
This approach can also be used to test the efficacy of potential therapies that target splicing defects, such as ASO-mediated exon skipping or splice site correction.
Overall, the antisense method is a powerful tool for studying splicing-associated diseases and developing new therapies for these conditions.
splicing deterioration in terminal stage:
I’m not sure what you mean by “splicing deterioration in terminal stage.” Can you please provide more context or.
information about what you are referring to? That way, I can better understand your question and provide you with a helpful response.
Amelioration of SMA-like symptoms by a therapeutic ASO:
Spinal Muscular Atrophy (SMA) is a genetic disease that affects the nervous system and causes muscle weakness and atrophy.
SMA is caused by mutations in the SMN1 gene, which leads to a deficiency in the survival motor neuron (SMN) protein.
Antisense oligonucleotides (ASOs) are a promising therapeutic approach for treating SMA:
ASOs are small, synthetic pieces of RNA that can bind to specific messenger RNAs (mRNAs) and alter their expression or function.
In the case of SMA, ASOs can target the SMN2 gene, which produces a similar but less stable version of the SMN protein.
By promoting the inclusion of exon 7 in SMN2 mRNA:
ASOs can increase the production of the functional SMN protein, thereby improving motor function and survival in SMA patients.
Several clinical trials have demonstrated the efficacy and safety of ASO:
based therapies for SMA. One such therapy is nusinersen (Spinraza), which was approved by the FDA in 2016 for the treatment of SMA.
Nusinersen is an ASO that targets the SMN2 gene and has been shown to improve motor function and survival in both infantile and later-onset SMA.
Another ASO-based therapy for SMA is risdiplam (Evrysdi):
which was approved by the FDA in 2020. Risdiplam also targets the SMN2 gene and has been shown to improve motor function in patients with type 1, 2, or 3 SMA.
In conclusion, ASO-based therapies targeting the SMN2 gene have shown great:
promise in ameliorating the symptoms of SMA. Nusinersen and risdiplam are two such therapies that have been approved by the FDA and are currently being used to treat SMA patients.